Macular Degeneration Treatment Market Report Examines Industry Trends, Growth Drivers And Future Outlook

The market for macular degeneration treatments is poised for significant expansion as new therapies and technologies emerge. With an aging global population and increasing healthcare investments, this sector is capturing the attention of researchers, companies, and patients alike. Let's explore the current market value, key players, emerging trends, and the major segments that define this growing field.

Projected Market Value and Growth Trajectory of the Macular Degeneration Treatment Market
The macular degeneration treatment market is anticipated to experience rapid expansion over the coming years, reaching a valuation of $20.74 billion by 2030. This corresponds to a compound annual growth rate (CAGR) of 10.7%. The surge in market size can be mainly attributed to the global rise in the elderly population, heightened investments in cutting-edge retinal therapies, increasing emphasis on early detection and management of age-related macular degeneration (AMD), wider adoption of gene and regenerative treatments, and escalating healthcare expenditures directed toward vision care. Key trends expected to influence the market include a stronger focus on early diagnosis, expanding use of anti-VEGF therapies, growing demand for treatments that preserve long-term vision, broader availability of minimally invasive options, and rising public awareness about age-related eye conditions.

The macular degeneration treatment market size has grown rapidly in recent years. It will grow from $12.38 billion in 2025 to $13.81 billion in 2026 at a compound annual growth rate (CAGR) of 11.5%. The growth in the historic period can be attributed to aging global population, increased prevalence of age-related macular degeneration, clinical success of anti-vegf injections, improved ophthalmic diagnostic capabilities, growing access to specialized eye care services.

Download a free sample of the macular degeneration treatment market report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=5799&type=smp&utm_source=OpenPR&utm_medium=Paid&utm_campaign=Aug_PR

Prominent Companies Leading the Macular Degeneration Treatment Industry
The competitive landscape of the macular degeneration treatment market features several notable organizations, including F Hoffmann La Roche Ltd, Regeneron Pharmaceuticals Inc, Novartis AG, Bayer AG, Allergan Inc, Bausch Health Companies Inc, Santen Pharmaceutical Co Ltd, Alimera Sciences Inc, Apellis Pharmaceuticals Inc, Iveric Bio Inc, Aerie Pharmaceuticals Inc, Kodiak Sciences Inc, Neurotech Pharmaceuticals Inc, Regenxbio Inc, Adverum Biotechnologies Inc, Applied Genetic Technologies Corp, 4D Molecular Therapeutics Inc, GenSight Biologics SA, Nanoscope Therapeutics Inc, Annexon Inc, Ocular Therapeutix Inc, and Graybug Vision Inc.

In a notable development, Harrow Inc., a US-based firm, completed the acquisition of Santen Pharmaceutical Co., Ltd. in July 2023 for $8 million. This strategic purchase is intended to broaden Harrow's portfolio by incorporating Santen's expertise and product offerings focused on macular degeneration treatments. Santen itself is a Japan-headquartered company known for its work in this therapeutic area.

View the full macular degeneration treatment market report:
https://www.thebusinessresearchcompany.com/report/macular-degeneration-treatment-global-market-report?utm_source=OpenPR&utm_medium=Paid&utm_campaign=Aug_PR

Emerging Trends and Opportunities Shaping the Macular Degeneration Treatment Sector
A significant focus within the market lies in the development of biosimilars to improve patient access to effective AMD therapies. Biosimilars are biological products designed to be highly similar to an already authorized reference medicine, with no meaningful differences in safety, purity, or efficacy. For example, in May 2024, Biocon Biologics Ltd from India and Samsung Bioepis Co. Ltd from South Korea secured FDA approvals for two biosimilars named Yesafili and Opuviz. Both these treatments act by inhibiting vascular endothelial growth factor (VEGF), which plays a key role in the abnormal growth of blood vessels in the eye-a common cause of vision loss in AMD and diabetic retinopathy. The FDA's approval process included thorough comparative studies demonstrating that these biosimilars match the safety and effectiveness of the reference product Eylea, based on rigorous assessments of pharmacokinetics and immunogenicity.

Market Segments Explaining the Macular Degeneration Treatment Industry's Structure
The macular degeneration treatment market is categorized into several important segments to reflect the disease stage, mode of administration, and user type. The stages include Early-Stage AMD, Intermediate AMD, and Late-Stage AMD. Administration routes are divided into Oral, Injectable, and Other Routes of Administration. End users primarily consist of Ambulatory Surgical Centers, Ophthalmic Clinics, and Hospitals.

Further breakdown of stages reveals specific types of treatments: Early-Stage AMD involves nutritional supplements and lifestyle modifications; Intermediate AMD focuses on regular disease monitoring, imaging surveillance, risk-factor management, and lifestyle changes; and Late-Stage AMD encompasses surgical interventions, advanced anti-VEGF therapies, and gene therapy options. This detailed segmentation helps provide a clear understanding of how the market addresses the varying needs of patients at different stages of macular degeneration.

New analytical features added to our 2026 market reports:

• Market attractiveness scoring and analysis
• Total addressable market (TAM) analysis
• Company scoring matrix graphics and tables
• Excel-based forecasting dashboards
• Market hotspots infographics
• Key technologies and future trend analysis
• Updated graphics and tables

Reach out to us:
The Business Research Company: https://www.thebusinessresearchcompany.com/,
Americas +1 310-496-7795,
Europe +44 7882 955267,
Asia & Others +44 7882 955267 & +91 8897263534,
Email us at info@tbrc.info.

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
With over 17500+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.